Share your videos with the world

Sign Up | Log In | Help  

   
 
Related Tags: health  schizophrenia  treatment  fieldwork  medical  mind  mental  janssen  multivu  7947151  science  technology  health  medical  award  biologist  yoshinori  ohsumi  research  cure  multivu  7856351  johnson  johnson  biopharmaceutical  idea  pharma  neuroscience  medicine  health  innovation  multivu  7770851  janssen  imbruvica  leukaemia  lymphoma  blood  cancer  treatment  multivu  72762540  mental  health  integration  index  mhi  index  illness  european  treatment  policy  healthcare  multivu  multivu  72762557  mental  health  integration  index  mhi  index  panel  illness  multivu  72762557  janssen  viral  hepatitis  c  economist  intelligence  unit  report  liver  disease  cancer  public  health  multivu  71400562  janssen  healthcare  innovation  care4today  mobile  health  manager  schedule  medication  reminder  app  multivu  62572  doctor  paul  janssen  award  scientific  thought  biomedical  research  investment  innovation  science  multivu  63340  hepatitis  c  hcv  pandemic  health  infectious  disease  treatments  policy  prevention  healthcare  multivu  58671  dr  paul  janssen  award  biomedical  research  science  health  medical  innovation  technological  advances  multivu  58019  janssen  healthcare  innovation  connected  care  challenge  hospital  patient  discharge  health  multivu  56342 
Search // janssen
Results 1-12 of 14 for ' janssen ' (0 seconds)
On World Mental Health Day, Janssen has announced the results of a pan-European research project: ‘Talking About Treatment in Schizophrenia: A Patient and Carer Survey’. The survey of 166 adults living with schizophrenia and 468 carers was conducted by the independent market research agency, Fieldwork International (part of Ipsos MORI), and explored awareness, feelings and preferences regarding treatment. The survey, conducted across 12 countries in Europe (Austria, Belgium, Denmark, France, Germany, Italy, Netherlands, Russia, Spain, Sweden, Switzerland and the UK), highlighted key factors affecting the peace of mind for carers, such as the impact of the condition on day‑to-day life, potential relapse/hospitalisation and getting support beyond medication. 94% stated they reminded the person they care for to take their medication and for 49% this happens often. To view the multimedia release go to: http://www.multivu.com/players/uk/7947151-janssen-survey-carers-adults-schizophrenia/
Categories // Miscellaneous 
Added: 709 days ago by MultiVuVideos
Runtime: 4m15s | Views: 84 | Comments: 0
Not yet rated
 

 

 

As part of an ongoing commitment to support life sciences innovators and the development of integrated, cross-sector solutions to prevent, intercept and cure diseases, Johnson & Johnson today named cell biologist Yoshinori Ohsumi, Ph.D., of the Tokyo Institute of Technology the winner of the 2016 Dr. Paul Janssen Award for Biomedical Research for his pioneering discoveries concerning the molecular basis of autophagy. Dr. Ohsumi was honored today during an event at the 2016 BIO International Convention in San Francisco. A video of his acceptance comments can be viewed here. “Dr. Ohsumi’s curiosity led him to become the first person in the world to determine the molecular mechanism and regulation of autophagy, shedding light on one of the most basic functions of all living cells,” said Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson. “Dr. Ohsumi’s discoveries hold promise for better understanding, preventing and treating many diseases. It is with great pleasure that we celebrate his contributions, which remind us of the innovative spirit Dr. Paul brought to the lab every day.” To view the multimedia release go to: http://www.multivu.com/players/English/7856351-2016-dr-paul-janssen-award-ohsumi/
Categories // Miscellaneous 
Added: 832 days ago by MultiVuVideos
Runtime: 1m37s | Views: 220 | Comments: 0
Not yet rated
 

 

 

The sixth annual Productive Innovation Index released by IDEA Pharma today, which ranks biopharmaceutical companies by their ability to successfully bring innovations to market, sees Johnson & Johnson top the industry for the fourth year running. The Productive Innovation Index measures, scores and celebrates a company’s ability to deliver innovation to patients, by objectively evaluating performance data based on a rolling five year period (2010-2015), and operates on the premise: if you gave the same molecule to two different companies in early phase, which would make the best of it? The success of the Janssen Pharmaceutical Companies of Johnson & Johnson and its consolidation of 1st place across the past four years’ rankings is driven largely by innovations in the field of oncology, immunology, neuroscience and cardiovascular/metabolism. Notable performers include Zytiga® (prostate cancer), Imbruvica® (chronic lymphocytic leukemia and mantle cell lymphoma (co-developed and co-marketed with Pharmacyclics, an AbbVie company)), Simponi®/Simponi Aria® (rheumatoid arthritis), Stelara® (psoriasis and psoriatic arthritis), Invega Sustenna® and Invega Trinza® (schizophrenia). To view the multimedia release go to: http://www.multivu.com/players/uk/7770851-johnson-and-johnson-tops-idea-pharma/
Categories // Miscellaneous 
Added: 936 days ago by MultiVuVideos
Runtime: 3m36s | Views: 159 | Comments: 0
Not yet rated
 

 

 

Janssen-Cilag International NV (Janssen) announced today that the European Commission has approved IMBRUVICA™ (ibrutinib) capsules, a first-in-class, once-daily, oral Bruton’s tyrosine kinase (BTK) inhibitor. This new approach to treating blood cancers works by blocking BTK, a protein that helps certain cancer cells live and grow.1 IMBRUVICA is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), or adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy. To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762540-janssen-ec-approval-imbruvica-mcl-cll/
Categories // People and Blog  Business 
Added: 1432 days ago by MultiVuVideos
Runtime: 1m39s | Views: 376 | Comments: 2
Not yet rated
 

 

 

Ahead of World Mental Health Day, today sees the publication of the Mental Health Integration Index, a new research initiative commissioned by the Janssen Pharmaceutical Companies of Johnson & Johnson and undertaken by the Economist Intelligence Unit.1 The research explores the challenges of integrating Europeans with mental illness into society and employment, within the European Union’s 28 Member States, plus Norway and Switzerland. Countries have been ranked according to their degree of commitment to support those living with mental illness; the findings demonstrate that while there are many examples of good practice across Europe, the whole region has a long way to go before people with mental illness are adequately supported and truly integrated into their communities. To view the Multimedia News Release, go to: http://www.multivu.com/players/English/72762557-janssen-europe-mental-health-index/
Categories // Miscellaneous 
Added: 1440 days ago by MultiVuVideos
Runtime: 2m26s | Views: 322 | Comments: 1
Not yet rated
 

 

 

Ahead of World Mental Health Day, today sees the publication of the Mental Health Integration Index, a new research initiative commissioned by the Janssen Pharmaceutical Companies of Johnson & Johnson and undertaken by the Economist Intelligence Unit.1 The research explores the challenges of integrating Europeans with mental illness into society and employment, within the European Union’s 28 Member States, plus Norway and Switzerland. Countries have been ranked according to their degree of commitment to support those living with mental illness; the findings demonstrate that while there are many examples of good practice across Europe, the whole region has a long way to go before people with mental illness are adequately supported and truly integrated into their communities. To view the Multimedia News Release, go to: http://www.multivu.com/players/English/72762557-janssen-europe-mental-health-index/
Categories // Miscellaneous 
Added: 1440 days ago by MultiVuVideos
Runtime: 1m31s | Views: 333 | Comments: 1
Not yet rated
 

 

 

‘Tackling hepatitis C: Moving towards an integrated policy approach’, a report published by The Economist Intelligence Unit (EIU) today reveals that many countries around the world have been slow to respond with national policies on hepatitis C despite recent government pledges to fight the disease. The hepatitis C virus remains the leading cause of liver cancer, liver disease and liver transplantation placing a huge burden on patients' lives and healthcare systems. To view the Multimedia News Release, go to http://www.multivu.com/mnr/71400562-janssen-new-reports-hepatitis-c
Categories // People and Blog 
Added: 1547 days ago by MultiVuVideos
Runtime: 5m28s | Views: 501 | Comments: 1
Not yet rated
 

 

 

Janssen Healthcare Innovation, a team within Janssen Research & Development, LLC focusing on optimizing healthcare delivery, announced today the launch of Care4Today™ Mobile Health Manager 2.0 (mhm.care4today.com). This free mobile platform and website is designed to help people stay on schedule with their medications with special features such as Care4Family™ and Care4Charity™ to support and motivate users to take their medications regularly. To view Multimedia News Release, go to http://www.multivu.com/mnr/62572-janssen-healthcare-innovation-launches-care4today-mobile-health-manager
Categories // Business  Science and Technology 
Added: 1819 days ago by MultiVuVideos
Runtime: 3m29s | Views: 1249 | Comments: 1
Not yet rated
 

 

 

Investment in basic research, convergence across disciplines and better engagement between academia and industry are key to the future of innovation, according to a panel of renowned thought leaders speaking at the celebration of the 2013 Dr. Paul Janssen Award for Biomedical Research. To view Multimedia News Release, go to http://www.multivu.com/mnr/63340-johnson-and-johnson-dr-paul-janssen-global-innovation-thermosensation
Added: 1825 days ago by MultiVuVideos
Runtime: 2m13s | Views: 1435 | Comments: 1
Not yet rated
 

 

 

A new Economist Intelligence Unit (EIU) report titled The Silent Pandemic: Tackling Hepatitis C with Policy Innovation, made possible as a result of an educational grant from Janssen Pharmaceutica NV and published today, highlights the urgent need for countries around the world to develop strategies to tackle head-on the growing social and economic issues associated with Hepatitis C (HCV). While the total number of infected individuals is unknown due to a lack of available data, the World Health Organization (WHO) estimates that approximately 150 million people globally are currently living with the blood-borne infectious disease, HCV. Of these, up to two thirds will develop chronic liver disease and one in five will develop cirrhosis. HCV is also the leading cause of liver transplantation worldwide and in the US the disease now accounts for more deaths than HIV. To view Multimedia News Release, go to http://www.multivu.com/mnr/58671-janssen-silent-pandemic-hepatitis-c
Categories // News and Politics 
Added: 2072 days ago by MultiVuVideos
Runtime: 1m30s | Views: 1272 | Comments: 1
Not yet rated
 

 

 

Johnson & Johnson today honors the winners of the 2012 Dr. Paul Janssen Award for Biomedical Research in a ceremony and scientific symposium at the New York Academy of Sciences in New York, NY. Victor Ambros, Ph.D., of the University of Massachusetts Medical School, and Gary Ruvkun, Ph.D., of Massachusetts General Hospital and Harvard Medical School, received the award for their collaborative discovery of microRNAs (miRNAs) as central regulators of gene expression and development, and will share a $100,000 prize. To view Multimedia News Release, go to http://www.multivu.com/mnr/58019-johnson-and-johnson-jnj-2012-dr-paul-janssen-award-for-biomedical-research
Added: 2202 days ago by MultiVuVideos
Runtime: 0m57s | Views: 4306 | Comments: 0
Not yet rated
 

 

 

Janssen Healthcare Innovation, a team within Janssen Research & Development, LLC (Janssen), today announced Discharge Decision Support System (D2S2) is the winner of the crowdsourcing-inspired Janssen Connected Care Challenge and the $100,000 prize. D2S2 is a discharge decision support system that uses a proprietary algorithm to assemble and score key data upon hospital admission in order to identify patients who should be referred to post-acute care services to reduce the risk of 30-day readmissions. To view Multimedia News Release, go to http://www.multivu.com/mnr/56342-discharge-decision-support-system-janssen-connected-care-challenge
Categories // Business  Science and Technology 
Added: 2309 days ago by MultiVuVideos
Runtime: 3m25s | Views: 4225 | Comments: 1
Not yet rated
 

 

 

Page 1 of 2  |  Go to page    Next» LAST»»



About Us   |   Help  |   Advertise on ClipMoon   |   Terms of Use   |   Privacy Policy   |   Copyright   |   Contact   |   Link us   |   RSS 
Copyright © 2007-2018 ClipMoon.com. All rights reserved.